The optimal functioning of genes in our body is essential for our wellbeing. However, there is a probability that we might inherit a defective gene which codes for a certain illness. This is sure to leave you frustrated. Not anymore though – gene therapy is advancing rapidly to prevent and treat such disabilities. Through unending research, scientists have uncovered ways to modify genes and replace faulty ones with healthy genes, to cure or prevent a disease or medical condition.

3H has successfully collaborated with The National Centre for Child Health and Development (国立研究開発法人：国立成育医療研究センター) to be part of this cutting edge technology. Gene therapy patients enrolled in clinical studies are closely observed and analyzed by 3H Digital Health devices for their long term health and safety. Pediatrics patients form a large proportion of subjects undergoing gene cell therapy due to their congenital genetic conditions. Thus a long term follow-up into their adulthood ensures their health safety.

Revolutionizing the field of Health-Tech, 3H is actively assisting these Pediatrics patients in their daily collection of safety and efficacy data. Children have their daily routine of schooling, and collection of data should not hinder their daily activities but adequate steps taken to simultaneously watch their health. Thus, 3H has introduced a very user-friendly mobile app where health data of these children are routed to clinicians real time who analyze the results for health and safety.

3H is actively assisting these Pediatrics patients in their daily collection of safety and efficacy data.

Promoting Gene Therapy: Gene cell therapy is the latest medical advancement in Japan and world over. This new field of disease prevention and treatment is still unknown to many. The National Center for Child Health Development is conducting awareness programs about this new technique with pharmaceutical companies and medical institutions to gain more popularity in this field. 3H has served as a helping hand working closely in establishing the Gene & Cell Therapy Awareness Unit, to disseminate information about gene technology to the public domain. 

Current Gene Therapy Studies in Japan: Gene therapy is the new treatment line for rare Pediatrics diseases. There is hope that 54% of such diseases can be solved through gene therapy. B-cell lymphoblastic leukaemia, the most common cancer in children and spinal muscular atrophy can be treated successfully through gene therapy. Gene therapy remains the future of medicine, however, as it’s in its infancy, it is important to study the long term safety and efficiency of this procedure, especially because children are a large part of these studies. It is important that children are been monitored till adulthood.

Clinical Monitoring by 3H: Gene therapy patients are closely monitored through a mobile application and the ePRO which is an electronic patient diary by 3H, helps the subjects undergoing clinical trials to enter their day to day life activities in an accurately and timely manner. The 3H in house developed P-Guardian system builds a close interaction between patients with their clinician for timely intervention of medical alerts. Patient retention is improved while there is a close follow up of trial patients, maintaining confidentiality of data. Long term follow up is the call for gene therapy patients at the moment, and 3H has successfully brought comfort to patients for their long term follow up routines.

3H connects human health with happiness. Being in the clinical research industry for over a decade, 3H has successfully integrated Health and Technology to provide solutions to the health care industry.

To know more about 3H approach for Pediatrics gene study in Japan, please contact imran@3h-ms.co.jp